These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 21228900)

  • 1. Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss.
    Trouvin AP; Goëb V
    Clin Interv Aging; 2010 Nov; 5():345-54. PubMed ID: 21228900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coptisine inhibits RANKL-induced NF-κB phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL and OPG gene expression in osteoblastic cells.
    Lee JW; Iwahashi A; Hasegawa S; Yonezawa T; Jeon WB; Cha BY; Nagai K; Woo JT
    J Nat Med; 2012 Jan; 66(1):8-16. PubMed ID: 21656335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Denosumab: RANKL inhibition in the management of bone loss.
    Hamdy NA
    Drugs Today (Barc); 2008 Jan; 44(1):7-21. PubMed ID: 18301800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab.
    Lacey DL; Boyle WJ; Simonet WS; Kostenuik PJ; Dougall WC; Sullivan JK; San Martin J; Dansey R
    Nat Rev Drug Discov; 2012 May; 11(5):401-19. PubMed ID: 22543469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
    Peng S; Liu XS; Huang S; Li Z; Pan H; Zhen W; Luk KD; Guo XE; Lu WW
    Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of OPG/RANK/RANKL gene expression levels in peripheral blood mononuclear cells (PBMC) after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis.
    Stuss M; Rieske P; Cegłowska A; Stêpień-Kłos W; Liberski PP; Brzeziańska E; Sewerynek E
    J Clin Endocrinol Metab; 2013 May; 98(5):E1007-11. PubMed ID: 23543663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Molecular mechanisms of action of bisphosphonates and strontium ranelate].
    Vengerovskiĭ AI; Khlusov IA; Nechaev KA
    Eksp Klin Farmakol; 2014; 77(9):43-6. PubMed ID: 25365870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.
    Kostenuik PJ; Nguyen HQ; McCabe J; Warmington KS; Kurahara C; Sun N; Chen C; Li L; Cattley RC; Van G; Scully S; Elliott R; Grisanti M; Morony S; Tan HL; Asuncion F; Li X; Ominsky MS; Stolina M; Dwyer D; Dougall WC; Hawkins N; Boyle WJ; Simonet WS; Sullivan JK
    J Bone Miner Res; 2009 Feb; 24(2):182-95. PubMed ID: 19016581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of the RANKL/RANK/OPG system.
    Yasuda H
    J Bone Miner Metab; 2021 Jan; 39(1):2-11. PubMed ID: 33389131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Updates on the role of receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand/osteoprotegerin pathway in breast cancer risk and treatment.
    Bayer CM; Beckmann MW; Fasching PA
    Curr Opin Obstet Gynecol; 2017 Feb; 29(1):4-11. PubMed ID: 28002265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do RANKL inhibitors (denosumab) affect inflammation and immunity?
    Ferrari-Lacraz S; Ferrari S
    Osteoporos Int; 2011 Feb; 22(2):435-46. PubMed ID: 20571772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Control of bone resorption by RANKL-RANK system].
    Harada S; Takahashi N
    Clin Calcium; 2011 Aug; 21(8):1121-30. PubMed ID: 21814016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteoprotegerin as a potential therapy for osteoporosis.
    Hamdy NA
    Curr Osteoporos Rep; 2005 Dec; 3(4):121-5. PubMed ID: 16303111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strontium ranelate inhibits key factors affecting bone remodeling in human osteoarthritic subchondral bone osteoblasts.
    Tat SK; Pelletier JP; Mineau F; Caron J; Martel-Pelletier J
    Bone; 2011 Sep; 49(3):559-67. PubMed ID: 21700005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
    Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
    Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RANKL inhibition for the management of patients with benign metabolic bone disorders.
    Anastasilakis AD; Toulis KA; Polyzos SA; Terpos E
    Expert Opin Investig Drugs; 2009 Aug; 18(8):1085-102. PubMed ID: 19558335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-20 differentially regulates bone mesenchymal stem cell activities in RANKL-induced osteoclastogenesis through the OPG/RANKL/RANK axis and the NF-κB, MAPK and AKT signalling pathways.
    Meng B; Wu D; Cheng Y; Huang P; Liu Y; Gan L; Liu C; Cao Y
    Scand J Immunol; 2020 May; 91(5):e12874. PubMed ID: 32090353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review).
    Liu W; Zhang X
    Mol Med Rep; 2015 May; 11(5):3212-8. PubMed ID: 25572286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The OPG/RANKL/RANK system and bone resorptive disease].
    Liu JZ; Ji ZL; Chen SM
    Sheng Wu Gong Cheng Xue Bao; 2003 Nov; 19(6):655-60. PubMed ID: 15971575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skeletal and extraskeletal actions of denosumab.
    Sinningen K; Tsourdi E; Rauner M; Rachner TD; Hamann C; Hofbauer LC
    Endocrine; 2012 Aug; 42(1):52-62. PubMed ID: 22581255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.